Reviews - 3da6 mentioned but not cited (1)
- Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Lee YT, Tan YJ, Oon CE. Acta Pharm Sin B 13 478-497 (2023)
Articles - 3da6 mentioned but not cited (3)
- Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. Da C, Zhang D, Stashko M, Vasileiadi E, Parker RE, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, Earp HS, Graham DK, Frye SV, Wang X, Kireev D. J Am Chem Soc 141 15700-15709 (2019)
- Fragment-Based and Structural Investigation for Discovery of JNK3 Inhibitors. Duong MTH, Ahn HC. Pharmaceutics 14 1900 (2022)
- Screening and Isolation of Potential Anti-Inflammatory Compounds from Saxifraga atrata via Affinity Ultrafiltration-HPLC and Multi-Target Molecular Docking Analyses. Li G, Fang Y, Ma Y, Dawa Y, Wang Q, Gan J, Dang J. Nutrients 14 2405 (2022)
Reviews citing this publication (2)
- The therapeutic journey of benzimidazoles: a review. Bansal Y, Silakari O. Bioorg. Med. Chem. 20 6208-6236 (2012)
- New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs. Shan Y, Wang B, Zhang J. Med Res Rev 38 1674-1705 (2018)
Articles citing this publication (15)
- A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis. Lin KT, Lien JC, Chung CH, Kuo SC, Huang TF. Eur. J. Pharmacol. 630 53-60 (2010)
- DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. Buchanan CM, Shih JH, Astin JW, Rewcastle GW, Flanagan JU, Crosier PS, Shepherd PR. Clin. Sci. 122 449-457 (2012)
- Catalyst-controlled chemoselective arylation of 2-aminobenzimidazoles. Ueda S, Buchwald SL. Angew. Chem. Int. Ed. Engl. 51 10364-10367 (2012)
- A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation. Radi M, Evensen L, Dreassi E, Zamperini C, Caporicci M, Falchi F, Musumeci F, Schenone S, Lorens JB, Botta M. Bioorg. Med. Chem. Lett. 22 5579-5583 (2012)
- Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. Sanphanya K, Wattanapitayakul SK, Phowichit S, Fokin VV, Vajragupta O. Bioorg. Med. Chem. Lett. 23 2962-2967 (2013)
- Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability. Harrington PE, Biswas K, Malwitz D, Tasker AS, Mohr C, Andrews KL, Dellamaggiore K, Kendall R, Beckmann H, Jaeckel P, Materna-Reichelt S, Allen JR, Lipford JR. ACS Med Chem Lett 6 68-72 (2015)
- Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases. McClellan WJ, Dai Y, Abad-Zapatero C, Albert DH, Bouska JJ, Glaser KB, Magoc TJ, Marcotte PA, Osterling DJ, Stewart KD, Davidsen SK, Michaelides MR. Bioorg. Med. Chem. Lett. 21 5620-5624 (2011)
- A zebrafish in vivo phenotypic assay to identify 3-aminothiophene-2-carboxylic acid-based angiogenesis inhibitors. Papakyriakou A, Kefalos P, Sarantis P, Tsiamantas C, Xanthopoulos KP, Vourloumis D, Beis D. Assay Drug Dev Technol 12 527-535 (2014)
- Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents. Temirak A, Shaker YM, Ragab FA, Ali MM, Ali HI, El Diwani HI. Eur J Med Chem 87 868-880 (2014)
- Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA, Abdel-Mohsen HT, El Kerdawy AM, Ragab FAF, Ali MM, Abu-Bakr SM, Girgis AS, El Diwani HI. Eur J Med Chem 136 315-329 (2017)
- Nickel-catalyzed Chan-Lam cross-coupling: chemoselective N-arylation of 2-aminobenzimidazoles. Kumar KA, Kannaboina P, Rao DN, Das P. Org. Biomol. Chem. 14 8989-8997 (2016)
- Synthesis, biological evaluation, and docking studies of new 2-furylbenzimidazoles as anti-angiogenic agents: part II. Temirak A, Shaker YM, Ragab FA, Ali MM, Soliman SM, Mortier J, Wolber G, Ali HI, El Diwani HI. Arch. Pharm. (Weinheim) 347 291-304 (2014)
- Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors. Arcari JT, Beebe JS, Berliner MA, Bernardo V, Boehm M, Borzillo GV, Clark T, Cohen BD, Connell RD, Frost HN, Gordon DA, Hungerford WM, Kakar SM, Kanter A, Keene NF, Knauth EA, Lagreca SD, Lu Y, Martinez-Alsina L, Marx MA, Morris J, Patel NC, Savage D, Soderstrom CI, Thompson C, Tkalcevic G, Tom NJ, Vajdos FF, Valentine JJ, Vincent PW, Wessel MD, Chen JM. Bioorg. Med. Chem. Lett. 23 3059-3063 (2013)
- Discovery of Pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors. Salerno S, Barresi E, García-Argáez AN, Taliani S, Simorini F, Amendola G, Tomassi S, Cosconati S, Novellino E, Da Settimo F, Marini AM, Dalla Via L. ACS Med Chem Lett 10 457-462 (2019)
- Theoretical Investigations on Interactions of Arylsulphonyl Indazole Derivatives as Potential Ligands of VEGFR2 Kinase. Czaja K, Kujawski J, Śliwa P, Kurczab R, Kujawski R, Stodolna A, Myślińska A, Bernard MK. Int J Mol Sci 21 (2020)